Interpace Biosciences, Inc.
IDXG
$0.9077
-$0.0823-8.31%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -19.83% | -6.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -19.83% | -6.50% | |||
| Cost of Revenue | -4.56% | 21.95% | |||
| Gross Profit | -28.41% | -17.35% | |||
| SG&A Expenses | 3.86% | -5.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.14% | 4.78% | |||
| Operating Income | -125.59% | -40.46% | |||
| Income Before Tax | -130.08% | -38.21% | |||
| Income Tax Expenses | -- | 325.00% | |||
| Earnings from Continuing Operations | -130.39% | -39.01% | |||
| Earnings from Discontinued Operations | 0.00% | -768.75% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -138.86% | -43.05% | |||
| EBIT | -125.59% | -40.46% | |||
| EBITDA | -119.07% | -39.25% | |||
| EPS Basic | -138.84% | -32.35% | |||
| Normalized Basic EPS | -130.05% | -38.37% | |||
| EPS Diluted | -357.93% | 15.43% | |||
| Normalized Diluted EPS | -288.25% | 11.11% | |||
| Average Basic Shares Outstanding | 0.07% | 0.27% | |||
| Average Diluted Shares Outstanding | -84.03% | -44.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||